Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of PRAX-944 in Participants With Essential Tremor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of ET consistent with Movement Disorders Society Criteria, a duration of ET of at least 3 years and with onset before the age of 65~2. TETRAS upper limb score (ie, sum of bilateral upper limb items 4a, 4b, and 4c) of ≥10 as rated by the Investigator at Screening and Baseline OR A score of ≥2 on 2 or more of the following TETRAS activities of daily living (ADL) subscale items: (2) Feeding with a spoon, (3) Drinking from a glass, (5) Dressing, (6) Pouring, (9) Writing OR A score of ≥2 on 1 of the following TETRAS ADL subscale items: (2) Feeding with a spoon, (3) Drinking from a glass, (5) Dressing, (6) Pouring, or (9) Writing AND a score of ≥2 on both of the following TETRAS ADL subscale items: (10) Working and (12) Social Impact~3. If currently receiving any medication for ET, is on a stable dose of any of these medications for ET for 28 days prior to Screening and is willing to maintain stable doses throughout the trial. If receiving primidone for ET, is willing and able to discontinue 14 days prior to Day 1.~4. Body mass index (BMI) between 18 and 40 kg/m2 (inclusive).~Exclusion Criteria:~1. Sporadically using a benzodiazepine, sleep medication, or anxiolytic that would confound the assessment of tremor.~2. Trauma to the nervous system within 3 months preceding the onset of tremor.~3. History of other medical, neurological or psychiatric condition that may explain or cause tremor, including but not limited to Parkinson's disease, dystonia, cerebellar disease, family history of Fragile X syndrome, traumatic brain injury, alcohol abuse or withdrawal, benzodiazepine abuse or withdrawal, multiple sclerosis, polyneuropathy, and endocrine states such as hyperthyroidism.~4. Prior magnetic resonance-guided focused ultrasound or surgical intervention for ET such as deep brain stimulation or thalamotomy.~5. Botulinum toxin injection for ET in the 6 months prior to Screening.~6. Unwilling or unable to refrain from alcohol 24 hours before and during clinical trial visits.~7. History of substance use disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: Open-label 20 and 40 mg PRAX-944 (Type: EXPERIMENTAL): Once daily, oral dosing with 7 days of 20 mg and 7 days of 40 mg
- Part B: Open-label titration PRAX-944 (120 mg) followed by blinded PRAX-944 (Type: EXPERIMENTAL): Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 28 days of 120 mg
- Part B: Open-label titration PRAX-944 (120 mg) followed by blinded placebo (Type: ACTIVE_COMPARATOR): Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 14 days of 120 mg, 14 days placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete